Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Moonlake Immunotherapeutics (NASDAQ: MLTX).The analyst commented, “Bimzelx was launched in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE